Peptide data sheet
PT-141
Sexual health · Bremelanotide · PT141
Verdict
promisingThe promising label reflects the human trial data behind the branded drug for one narrow use; research-grade PT-141 sold for lab use is not the same product and has a thinner safety picture.
Quick answer
PT-141 (bremelanotide) is a melanocortin-receptor peptide commonly researched for sexual arousal and desire. Unlike most research peptides it has real human trial data: that data supported the branded prescription drug Vyleesi, FDA-approved for one narrow use. Research-grade PT-141 sold for lab use is not that product and is not FDA-approved.
- Class
- Melanocortin receptor agonist (cyclic heptapeptide)
- Half-life
- roughly 2 to 3 hours (reported)
- FDA status
- Vyleesi (bremelanotide) is FDA-approved for one narrow use (premenopausal HSDD). Research-grade PT-141 sold for lab use is a different product intended for laboratory research only.
- WADA banned?
- No
Which form actually works?
Injectable (subcutaneous)
Promising
The form the human trials and the branded prescription drug used. People report the effect timing and the reported side effects here; it also carries the most research context of any form.
Intranasal
Unproven
An earlier research direction that people still ask about. It carries less consistent human data than the injectable path, and blood-pressure signals were part of why that direction was set aside.